Genetic testing: Costs and access to intensive care unit care

Critical Care Medicine

Volumn 31, Issue 5 SUPPL., 2003, Pages

  Pinsky, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic counseling; Healthcare resources; Intensive care medicine; Polymorphism; Sepsis; Single nucleotide polymorphism

Indexed keywords

CALCITONIN; CYTOKINE; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ACUTE DISEASE; ALLELE; CONGENITAL DISORDER; CONVALESCENCE; CRITICAL ILLNESS; DOCTOR PATIENT RELATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE LOCUS; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC SCREENING; HEALTH CARE ACCESS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; INDIVIDUALITY; INTENSIVE CARE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RESOURCE ALLOCATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

EID: 0037568118     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ccm.0000065277.22601.f6     Document Type: Review

References (27)

1. Center for Disease Control: Increase in national hospital discharge survey rates for septicemia: United States, 1979-1987. JAMA 1990; 263:937-938
2. Quartin AA, Schein RM, Kett DH, et al: Magnitude and duration of the effect of sepsis on survival. JAMA 1997; 277:1058-1063
3. Perl TM, Dvorak L, Hwang T, et al: Long-term survival and function after suspected Gram-negative sepsis. JAMA 1995; 274:338-345
4. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
5. Angus CD, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1309
6. Sands KE, Bates DW, Lanken PN, et al: Epidemiology of sepsis syndrome in 8 academic medical centers: Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997; 278:234-240
7. Schulman KA, Glick HA, Rubin H, et al: Cost-effectiveness of HA-1A monoclonal antibody for Gram-negative sepsis: Economic assessment of a new therapeutic agent. JAMA 1991; 266:3466-3471
8. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214
9. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
10. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
11. Remick D, Manohar P, Bolgos G, et al: Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 1995; 4:89-95
12. Echtenacher B, Falk W, Mannel DN, et al: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145:3762-3766
13. Sorensen TI, Nielsen GG, Andersen PK, et al: Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318:727-732
14. Westendorp RG, Langermans JA, de Bel CE, et al: Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis 1995; 171:1057-1060
15. Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191
16. Fang XM, Schroder S, Hoeft A, et al: Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27:1330-1334
17. Hurme M, Helminen M: Resistance to human cytomegalovirus infection may be influenced by genetic polymorphisms of the tumour necrosis factor-alpha and interleukin-1 receptor antagonist genes. Scand J Infect Dis 1998; 30:447-449
18. Halushka MK, Fan JB, Bentley K, et al: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999; 22:239-247
19. Wilson AG, Symons JA, McDowell TL, et al: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Nat Acad Sci U S A 1997; 94:3195-3199
20. Kroeger KM, Carville KS, Abraham LJ: The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34:391-399
21. Warzocha K, Ribeiro P, Bienvenu J, et al: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998; 91: 3574-3581
22. Mira JP, Cariou A, Grall F, et al: Association of TNF2, a TNF-a promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999; 282:561-568
23. Kumar A, Short J, Parrillo JE: Genetic factors in septic shock. JAMA 1999; 282:579-581
24. Leroy EM, Baize S, Volchkov VE, et al: Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000; 355:2210-2215
25. Shiota K: Maternal fertility, reproductive loss, and defective human embryos. J Epidemiol Community Health 1989; 43:261-267
26. Bennett MJ, Huey-Tubman KE, Herr AB, et al: A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Nat Acad Sci U S A 2002; 99:11634-11639
27. Rodriguez-Villar C, Casamitjana R, Conget I: Therapy to prevent type 1 diabetes mellitus. N Engl J Med 2002; 347:1115-1116